Archive for category: New Drugs for Melanoma

ASCO 2012 Melanoma Posters

0 / June 3, 2012 9:52 pm

ost will cover both the “discussed” posters, generally felt to be more important by ASCO organizers, and the “general” posters. Instead of going through all the posters, I have selected the ones I found most interesting: A phase II single […]

Anti-PD-1 Therapy

0 / June 2, 2012 5:14 am

CO press releases have begun; first up to the plate is BMS and their anti-PD-1 antibody. Similar to ipilimumab, this drug works through immune system checkpoint modulation.In other words, it works by releasing the natural inhibition of our immune […]

ASCO 2011 Plenary Part 2: Vemurafenib

3 / August 14, 2011 4:49 am

lanoma Triple-Threat   I was going over my notes about Dr. Paul Chapman’s ASCO 2011 Plenary Session presentation on the Phase III Vemurafenib study in metastatic melanoma and I came across an interesting phrase concerning the results: this is […]

Diphencyprone (DPCP) as Topical Agent to Treat Melanoma

0 / May 15, 2011 10:02 pm

s an inexpensive topical therapy that appears to have some efficacy in regionally advanced cutanous melanoma. In small numbers of patients, there is a significant response rate. I don’t believe it is approved in the United States but I […]

Rose Bengal (PV-10) at Melanoma Centers Meeting 2010

0 / May 15, 2011 9:59 pm

njiv Agarwala presented an update on Phase II trial of PV-10 oncolytic  injections (Provectus/Rose Bengal). Not really any new data presented but updates of new protocol plans discussed. Response rates: 24% CR / 25% PR in target lesions. Local […]

GSK BRAF Inhibitor With Early But Impressive Results

GSK BRAF Inhibitor With Early But Impressive Results

1 / May 15, 2011 9:52 pm

Presented by Rick Kefford, MD, from Melanoma Institute of Australia. This was a Phase I/II trial of this agent (colloquially called “436″) in melanoma. 112 patients were treated in a dose escalation construct, all with mutant BRAF melanomas. The […]

Ipilimumab at Plenary Session 2010

Ipilimumab at Plenary Session 2010

0 / May 15, 2011 9:39 pm

for the first time anybody can remember, a melanoma study was presented at the ASCO plenary. It was very exciting for me to see my good friend Steve O’Day from The Angeles Clinic standing in front of what is […]

BRAF Mutation and Inhibition at ASCO 2011

0 / April 1, 2010 11:00 pm

y, at ASCO 2011, several important presentations will take place regarding BRAF mutant inhibitor drugs. These drugs attack a specific mutation in the BRAF gene. Without getting too technical, the BRAF protein is involved in one of the key cell […]

Shopping Cart (0 Items)
Your cart is empty!

Subtotal: $0.00
Total: $0.00